Current management of peripheral t-cell lymphomas

M. Gooptu, R. Rhoades, B. Pro*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Peripheral T-cell lymphomas (PTCLs) are an uncommon group of lymphopro-liferative disorders accounting for approximately 10–15% of all non-Hodgkin lymphomas (NHL) in Western countries. Although PTCLs are associated with poor prognosis, outcomes vary with disease subtype. The standard of care has been anthracycline-based induction combination chemotherapy, however, with the exception of low-risk ALK-positive anaplastic large cell lymphoma, relapse rates are high. Therefore, consolidation with autologous stem cell transplantation is usually recommended for patients deemed candidates, and with aggressive subtypes. In recent years, a number of novel agents including pralatrexate, histone deacetylase inhibitors, immunotoxins, proteasome inhibitors, aurora kinase inhibitors and the CD30 antibody-drug conjugate brentuximab vedotin, have shown promise in the treatment of PTCLs. Studies are underway to explore the activity of these newer agents used in the frontline setting.

Original languageEnglish (US)
Pages (from-to)289-303
Number of pages15
JournalCancer treatment and research
StatePublished - 2015


  • Diagnosis
  • Lymphoma
  • Novel therapies
  • T-cell lymphoma
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Current management of peripheral t-cell lymphomas'. Together they form a unique fingerprint.

Cite this